Author's response to reviews

Title: Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Authors:

George Awad (GAwad@hrrh.on.ca)
Mariam Hassan (Mariam.Hassan@sunovion.com)
Antony Loebel (Antony.loebel@sunovion.com)
Jay Hsu (Jay.Hsu@sunovion.com)
Andrei Pikalov (Andrei.pikalov@sunovion.com)
Krithika Rajagopalan (Krithika.rajagopalan@sunovion.com)

Version: 2 Date: 29 July 2013

Author's response to reviews:

Changes Made as per EDITOR'S REQUEST:
Following text changes were added to the Methods section on page 6 of the manuscript to address comment 1 and 2:

Briefly, the study was conducted at 28 sites in the United States (ClinicalTrials.gov identifier: NCT01143077). The study protocol was reviewed and approved by an institutional review board at each study center, and the trial was conducted in accordance with Good Clinical Practice as required by the International Conference on Harmonization guidelines. Compliance with these requirements also constitutes conformity with the ethical principles of the Declaration of Helsinki. Subjects had to provide informed consent to participate in the study.

1. Requesting ethics statement:
Research involving human subjects (including human material or human data) that is reported in the manuscript must have been performed with the approval of an appropriate ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration (http://www.wma.net/en/30publications/10policies/b3/index.html). A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate.

2. Requesting consent statement:
Please state in the Methods section whether written informed consent for participation in the study was obtained from participants or, where participants are children, a parent or guardian.

3. We notice that the Health-related quality of life measures are not specified in
the TRN you have provided. Please could you provide a reason for why this might be, or an alternative TRN.

TRN listed only the clinical outcome measures on time to relapse and number of adverse events. Patient Reported Outcomes measures on health related quality of life are provided in the publication providing details of this clinical trial (McEvoy J. et al. J Clin Psychiatry 2013;74(2):170-9.)